These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29882921)

  • 1. Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers.
    Losi L; Fonda S; Saponaro S; Chelbi ST; Lancellotti C; Gozzi G; Alberti L; Fabbiani L; Botticelli L; Benhattar J
    Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29882921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype.
    Kolbe DL; DeLoia JA; Porter-Gill P; Strange M; Petrykowska HM; Guirguis A; Krivak TC; Brody LC; Elnitski L
    PLoS One; 2012; 7(3):e32941. PubMed ID: 22403726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
    Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
    Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.
    Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
    Indian J Med Res; 2014 Nov; 140(5):616-23. PubMed ID: 25579142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
    Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation profiling of esophageal adenocarcinoma using Methylation Ligation-dependent Macroarray (MLM).
    Guilleret I; Losi L; Chelbi ST; Fonda S; Bougel S; Saponaro S; Gozzi G; Alberti L; Braunschweig R; Benhattar J
    Biochem Biophys Res Commun; 2016 Oct; 479(2):231-237. PubMed ID: 27634218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
    Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
    Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array.
    Yoon MS; Suh DS; Choi KU; Sol MY; Shin DH; Park WY; Lee JH; Jeong SM; Kim WG; Shin NR
    Oncol Rep; 2010 Oct; 24(4):917-25. PubMed ID: 20811671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.
    Imura M; Yamashita S; Cai LY; Furuta J; Wakabayashi M; Yasugi T; Ushijima T
    Cancer Lett; 2006 Sep; 241(2):213-20. PubMed ID: 16303245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.
    Houshdaran S; Hawley S; Palmer C; Campan M; Olsen MN; Ventura AP; Knudsen BS; Drescher CW; Urban ND; Brown PO; Laird PW
    PLoS One; 2010 Feb; 5(2):e9359. PubMed ID: 20179752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
    Wilcox CB; Baysal BE; Gallion HH; Strange MA; DeLoia JA
    Cancer Genet Cytogenet; 2005 Jun; 159(2):114-22. PubMed ID: 15899382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
    Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.
    Dai W; Teodoridis JM; Zeller C; Graham J; Hersey J; Flanagan JM; Stronach E; Millan DW; Siddiqui N; Paul J; Brown R
    Clin Cancer Res; 2011 Jun; 17(12):4052-62. PubMed ID: 21459799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
    Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
    Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
    Ma L; Zhang JH; Liu FR; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets.
    Wu Q; Lothe RA; Ahlquist T; Silins I; Tropé CG; Micci F; Nesland JM; Suo Z; Lind GE
    Mol Cancer; 2007 Jul; 6():45. PubMed ID: 17623056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
    Schmid G; Notaro S; Reimer D; Abdel-Azim S; Duggan-Peer M; Holly J; Fiegl H; Rössler J; Wiedemair A; Concin N; Altevogt P; Marth C; Zeimet AG
    BMC Cancer; 2016 Feb; 16():102. PubMed ID: 26879132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of O⁶-methyguanine-DNA methyltransferase by promoter hypermethylation: association of epithelial ovarian carcinogenesis in specific histological types.
    Roh HJ; Suh DS; Choi KU; Yoo HJ; Joo WD; Yoon MS
    J Obstet Gynaecol Res; 2011 Jul; 37(7):851-60. PubMed ID: 21450028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.